Supplementary Figure 18 from Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer

Biagio Ricciuti; Arielle Elkrief; Joao V. Alessi; Xinan Wang; Yvonne Li; Hersh Gupta; Daniel M. Muldoon; Arrien A. Bertram; Federica Pecci; Giuseppe Lamberti; Alessandro Di Federico; Adriana Barrichello; Victor R. Vaz; Malini Gandhi; Elinton Lee; Geoffrey I. Shapiro; Hyesun Park; Mizuki Nishino; James Lindsay; Kristen D. Felt; Bijaya Sharma; Andrew D. Cherniack; Scott J. Rodig; Daniel R. Gomez; Narek Shaverdian; Mehrdad Rakaee; Chaitanya Bandlamudi; Marc Ladanyi; Pasi A. Jänne; Adam J. Schoenfeld; Lynette M. Sholl; Mark M. Awad; Michael L. Cheng

doi:10.1158/1078-0432.27031207.v1

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Supplementary Figure 18. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 immune checkpoint blockade monotherapy among patients with ATMMUT NSCLC, according to STK11 mutation. (D) Objective response rate, (E) progression-free survival, and (F) overall survival to PD-(L)1 immune checkpoint blockade in combination with platinum doublet chemotherapy among patients with ATMMUT NSCLC, according to STK11 mutation.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ricciuti et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db643587522f30 https://doi.org/10.1158/1078-0432.27031207.v1

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure 18 from Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Supplementary Figure 18 from Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading